Cargando…
How Azanucleosides Affect Myeloid Cell Fate
The azanucleosides decitabine and azacytidine are used widely in the treatment of myeloid neoplasia and increasingly in the context of combination therapies. Although they were long regarded as being largely interchangeable in their function as hypomethylating agents, the azanucleosides actually hav...
Autores principales: | Stein, Anna, Platzbecker, Uwe, Cross, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406747/ https://www.ncbi.nlm.nih.gov/pubmed/36010665 http://dx.doi.org/10.3390/cells11162589 |
Ejemplares similares
-
Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents
por: Gallimore, Fallon, et al.
Publicado: (2023) -
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
por: Diesch, Jeannine, et al.
Publicado: (2016) -
Efficient diastereoselective synthesis of a new class of azanucleosides: 2′-homoazanucleosides
por: Bouton, Jakob, et al.
Publicado: (2017) -
Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia
por: Molina, Manuel, et al.
Publicado: (2015) -
Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors
por: Pawlak, Alicja, et al.
Publicado: (2016)